I was diagnosed with MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) in 2022 via biopsy after persistently elevated liver enzymes. NAS score of 5 (steatosis 2, lobular inflammation 2, ballooning 1) with stage F2 fibrosis. Basically: significant fatty liver disease with active inflammation and early scarring.
Started semaglutide 2.4 mg in early 2024. Here's my liver panel trajectory:
| Marker | Pre-Sema (2023) | 6 Months | 12 Months | 18 Months (now) | Normal Range |
|---|---|---|---|---|---|
| ALT (U/L) | 88 | 42 | 26 | 18 | 7-56 |
| AST (U/L) | 64 | 38 | 24 | 20 | 10-40 |
| GGT (U/L) | 112 | 58 | 34 | 28 | 9-48 |
| Alk Phos (U/L) | 98 | 82 | 68 | 62 | 44-147 |
| FIB-4 Score | 2.8 | 1.9 | 1.4 | 1.1 | <1.3 low risk |
My hepatologist ordered a repeat FibroScan at month 12: CAP score dropped from 348 dB/m (severe steatosis) to 218 dB/m (mild steatosis). Liver stiffness went from 9.8 kPa (F2-F3) to 6.4 kPa (F0-F1).
I also lost 62 lbs (SW: 258 → CW: 196, 24% loss). My hepatologist says the imaging and labs are "consistent with MASH resolution" and is considering whether a repeat biopsy is warranted.
This is an outstanding response and it aligns with the Phase 2 trial data for semaglutide in MASH. In the semaglutide Phase 2b MASH trial, 59% of patients on semaglutide 0.4 mg daily achieved MASH resolution (defined as NAS ≤2 with no hepatocyte ballooning) vs. 17% on placebo.[1]
Your FibroScan improvements are particularly encouraging:
- CAP 348 → 218 dB/m: This represents a shift from S3 (severe) to S1 (mild) steatosis. That's a dramatic reduction in hepatic fat content.
- Stiffness 9.8 → 6.4 kPa: Crossing from F2-F3 to F0-F1 territory suggests fibrosis regression, which is the holy grail of MASH treatment. Fibrosis stage is the strongest predictor of liver-related mortality.
The mechanism involves multiple pathways: reduced de novo lipogenesis (from improved hepatic insulin sensitivity), increased fatty acid oxidation, reduced hepatic inflammation, and potentially direct anti-fibrotic effects through hepatic stellate cell modulation.
[1] Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
Regarding the repeat biopsy question: there's growing consensus that non-invasive testing (FibroScan + serum markers like FIB-4 and ELF score) can adequately monitor treatment response without subjecting patients to repeat biopsies. The AASLD is evolving its guidance on this.
Your FIB-4 improvement from 2.8 to 1.1 is very reassuring. A FIB-4 <1.3 has a >90% negative predictive value for advanced fibrosis. Combined with the FibroScan improvement, I think a repeat biopsy is reasonable to confirm resolution but probably not strictly necessary from a management standpoint.
The one scenario where I'd push for biopsy: if there's consideration of stopping semaglutide. Having histological confirmation of resolution would provide confidence that the underlying disease is truly addressed, not just biochemically suppressed.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFor context, here's the current therapeutic landscape for MASH and where GLP-1 agonists fit:
| Agent | Mechanism | MASH Resolution Rate | Fibrosis Improvement | FDA Approved for MASH? |
|---|---|---|---|---|
| Resmetirom (Rezdiffra) | THR-β agonist | ~30% | ~26% | Yes (2024) |
| Semaglutide 0.4mg daily | GLP-1 RA | ~59% | ~43% (no worsening) | No (Phase 3 ongoing) |
| Tirzepatide | GIP/GLP-1 RA | ~74% (Phase 2) | ~57% (Phase 2) | No (Phase 3 ongoing) |
| Pioglitazone | PPAR-γ agonist | ~47% | Limited | No (off-label use) |
| Lifestyle alone | ≥10% weight loss | ~40-50% | ~20-30% | N/A |
Tirzepatide's Phase 2 MASH data (SYNERGY-NASH) showed the highest resolution rates of any agent studied, likely due to the dual GIP/GLP-1 mechanism and greater weight loss. Phase 3 trials are ongoing and highly anticipated.
The tirzepatide MASH numbers are incredible. 74% resolution rate? I wonder if patients with more advanced fibrosis (F3-F4) would see similar benefit, or if there's a point of no return where the fibrosis is too established to reverse.